Head and neck cancer
Conditions
Interventions
TS-1 performed in alternate-day dosing
Sponsors
National Center for Global health and Medicine Otolarygology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Intended for cases corresponding to all of the following items. 1)Cases would be diagnosed with squamous cell carcinoma (except thyroid) primary tumor by histological or cytological diagnosis, curative treatment was performed.In addition, diagnostic imaging(chest X-ray, ultrasound, CT, MRI, such as PET) after two months followed by radiotherapy treatment and surgery (including combination therapy chemoradiation therapy) curative Tumor Free will be confirmed by it is defined as Ru. 2)Maxillary sinus, oral cavity, oropharynx , primary site, larynx (T3N0 glottic excluded) case is it or hypopharynx 3)Cases of IV A , IV B Stage III Stage or clinical or pathological stage 4)Case you do not have anti-cancer treatment until after the end of curative treatment initial registration 5)Patient age at the time of obtaining informed consent is 20 years of age or older 6)0-1 is a case: (PS Performance status) general condition 7)capable of oral intake 8)Patients with the following conditions are met in the bone marrow within 14 days prior to enrollment, liver and renal function i)WBC:>=3,500/mm3,<12,000/mm3 ii)neutrophil:>=1,500/mm3 iii)blood platelet:>=100,000mm3 iv)hemoglobin:>=9.0g/dL v)total bilirubin:=2.0mg/dL vi)AST(GOT):<=100IU/L ALT(GPT):<=100IU/L vii)Creatinine clearance:>= case is greater than or equal to 60ml/min
Exclusion criteria
Exclusion criteria: 1)It is contraindicated in patients with the administration of TS-1 2)Cases that are complicated by infection requiring treatment 3)Gastrointestinal disease with treatment (intestinal paralysis, intestinal obstruction, etc.) Patients with 4)Patients with interstitial pneumonitis or pulmonary fibrosis 5)Patients with diabetes 6)Patients with heart disease 7)Patients with (watery) diarrhea 8)Patients attending physician was deemed inappropriate as the subject of the study for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completion percentage administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event, Total dose for dose planning ,survival, recurrence-free survival | — |
Countries
Japan
Contacts
Public ContactTakahiro Asakage
Hospital School of Medicine,University of Tokyo Otolarygology,Auditory speech surgery
Outcome results
None listed